Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results conference call. My name is Sherry, and I'll be your operator for today. As a ...

Q4 2024 Earnings Call Transcript February 11, 2025 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.48 EPS, expectations were $0.51. Operator: Good day, ladies and gentlemen, and ...

Good day, ladies and gentlemen, and welcome to the Exelixis ... trial of zanza in NET in the first half of 2025 and anticipate Merck will initiate two RCC studies evaluating zanza plus belzutifan ...

Ladies and gentlemen, welcome to the Sobi Q4 2024 Report ... your 2024 EBITDA in light of a potential competitive launch by Merck ahead of the 2025, 2026 RSV season and the 100% margin ...

Merck Foundation marks World Cancer Day with African First Ladies by providing 194 scholarships of Oncology Training to African doctors from 32 countries. Merck Foundation together with Africa ...

Folk dancing should drop terms like “ladies and gentlemen” to avoid “offending minority genders”, a leading music organisation has said. The English Folk Dance and Song Society (EFDSS ...

Merck Foundation marks World Cancer Day with African First Ladies by providing 194 scholarships of Oncology Training to African doctors from 32 countries. Merck Foundation together with Africa First ...

Saturday Night Live is in the midst of its big 50th anniversary celebration, and earlier this week NBC premiered Ladies and Gentlemen…50 Years of SNL Music, a two-hour documentary directed by ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...